[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA200602100A1 - Соединения и способы для ингибирования митотической прогрессии - Google Patents

Соединения и способы для ингибирования митотической прогрессии

Info

Publication number
EA200602100A1
EA200602100A1 EA200602100A EA200602100A EA200602100A1 EA 200602100 A1 EA200602100 A1 EA 200602100A1 EA 200602100 A EA200602100 A EA 200602100A EA 200602100 A EA200602100 A EA 200602100A EA 200602100 A1 EA200602100 A1 EA 200602100A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
methods
mitotic progression
inhibiting mitotic
inhibiting
Prior art date
Application number
EA200602100A
Other languages
English (en)
Other versions
EA012112B1 (ru
Inventor
Кристофер Ф. Клейборн
Ллойд Дж. Пейн
Ричард Дж. Бойс
Тодд Б. Селлз
Стефен Г. Строуд
Стюарт Трейверс
Трициа Дж. Вос
Габриэл С. Уэзерхед
Original Assignee
Миллениум Фармасьютикалз, Инк
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Миллениум Фармасьютикалз, Инк filed Critical Миллениум Фармасьютикалз, Инк
Publication of EA200602100A1 publication Critical patent/EA200602100A1/ru
Publication of EA012112B1 publication Critical patent/EA012112B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Small-Scale Networks (AREA)

Abstract

Настоящее изобретение относится к соединениям и способам лечения рака. В частности, данное изобретение предлагает соединения, которые ингибируют ферменты Aurora-киназы, фармацевтические композиции,содержащие эти соединения, и способы применения соединений для лечения рака.
EA200602100A 2004-05-14 2005-05-12 Соединения и способы для ингибирования митотической прогрессии EA012112B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57165304P 2004-05-14 2004-05-14
US61722104P 2004-10-08 2004-10-08
PCT/US2005/016445 WO2005111039A2 (en) 2004-05-14 2005-05-12 Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase

Publications (2)

Publication Number Publication Date
EA200602100A1 true EA200602100A1 (ru) 2007-04-27
EA012112B1 EA012112B1 (ru) 2009-08-28

Family

ID=35262144

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200602100A EA012112B1 (ru) 2004-05-14 2005-05-12 Соединения и способы для ингибирования митотической прогрессии

Country Status (26)

Country Link
US (9) US7572784B2 (ru)
EP (4) EP1771450B9 (ru)
JP (4) JP4467616B2 (ru)
KR (3) KR101748290B1 (ru)
CN (1) CN104193750B (ru)
AR (1) AR049277A1 (ru)
AT (1) ATE381566T1 (ru)
AU (1) AU2005243175B2 (ru)
BR (1) BRPI0511139B8 (ru)
CA (1) CA2565411C (ru)
CY (2) CY1108092T1 (ru)
DE (1) DE602005003951T4 (ru)
DK (1) DK1771450T5 (ru)
EA (1) EA012112B1 (ru)
ES (3) ES2299080T3 (ru)
HK (4) HK1102500A1 (ru)
HR (2) HRP20080120T5 (ru)
IL (1) IL179063A (ru)
MX (1) MXPA06013042A (ru)
MY (1) MY139355A (ru)
NZ (1) NZ551370A (ru)
PL (1) PL1771450T3 (ru)
PT (2) PT1771450E (ru)
RS (2) RS52436B (ru)
TW (1) TWI338688B (ru)
WO (1) WO2005111039A2 (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8624027B2 (en) 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY139355A (en) 2004-05-14 2009-09-30 Millennium Pharm Inc Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase
EP2439207A1 (en) 2004-10-04 2012-04-11 Millennium Pharmaceuticals, Inc. Lactam Compounds Useful as Protein Kinase Inhibitors
TW200621759A (en) * 2004-10-29 2006-07-01 Banyu Pharma Co Ltd Novel aminopyridine derivatives having aurora A selective inhibitory action
CN101166732B (zh) 2005-04-28 2013-04-17 田边三菱制药株式会社 氰基吡啶衍生物及其作为药物的应用
PL1877098T3 (pl) * 2005-05-05 2013-09-30 Glaxosmithkline Ip Dev Ltd Koniugaty estru alfa-aminokwasu z lekiem ulegające hydrolizie z udziałem karboksyloesterazy
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
US7572809B2 (en) * 2005-12-19 2009-08-11 Hoffmann-La Roche Inc. Isoquinoline aminopyrazole derivatives
WO2007087246A2 (en) * 2006-01-24 2007-08-02 Merck & Co., Inc. Jak2 tyrosine kinase inhibition
CA2645731A1 (en) * 2006-03-15 2007-09-27 Wyeth N-substituted-azacyclylamines as histamine-3 antagonists
CN101405001A (zh) * 2006-03-20 2009-04-08 霍夫曼-拉罗奇有限公司 抑制btk和syk蛋白质激酶的方法
CA2649913A1 (en) * 2006-05-19 2007-11-29 Wyeth N-benzoyl- and n-benzylpyrrolidin-3-ylamines as histamine-3 antagonists
US7718648B2 (en) 2006-08-09 2010-05-18 Millennium Pharmaceuticals, Inc. Pyridobenzazepine compounds and methods for inhibiting mitotic progression
PE20081152A1 (es) * 2006-10-06 2008-08-10 Wyeth Corp Azaciclilaminas n-sustituidas como antagonistas de histamina-3
BRPI0719883A2 (pt) 2006-10-09 2015-05-05 Takeda Pharmaceutical Inibidores de quinase
JP5528807B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
JP5528806B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
AU2012203952B2 (en) * 2006-11-16 2014-12-11 Millennium Pharmaceuticals, Inc. Compounds for inhibiting mitotic progression
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
AU2014280932B2 (en) * 2006-11-16 2016-10-06 Millennium Pharmaceuticals, Inc. Compounds for inhibiting mitotic progression
EP2155719A1 (en) * 2007-05-24 2010-02-24 Wyeth LLC Azacyclylbenzamide derivatives as histamine-3 antagonists
TW200914457A (en) * 2007-05-31 2009-04-01 Kyowa Hakko Kogyo Kk Pyrimidodiazepinone derivative
PE20090812A1 (es) * 2007-07-16 2009-06-14 Wyeth Corp Derivados de aminoalquilazol como antagonistas de histamina-3
EA201000422A1 (ru) * 2007-09-04 2010-08-30 Биолипокс Аб Бисароматические соединения, применимые при лечении воспаления
TW200918062A (en) * 2007-09-12 2009-05-01 Wyeth Corp Azacyclylisoquinolinone and-isoindolinone derivatives as histamine-3 antagonists
CA2699384A1 (en) * 2007-09-12 2009-03-19 Wyeth Llc Isoquinolinyl and isoindolinyl derivatives as histamine-3 antagonists
JP2009108036A (ja) * 2007-09-28 2009-05-21 Fujifilm Corp 新規アセチレン化合物、その製造方法、それを構成単位として含むポリマー、該化合物及び／又は該ポリマーを含む組成物、該組成物を硬化させてなる硬化物
JP5555186B2 (ja) * 2008-02-29 2014-07-23 クロマ セラピューティクス リミテッド ｐ３８ＭＡＰキナーゼ阻害剤
GB0803747D0 (en) * 2008-02-29 2008-04-09 Martin Enzyme and receptor modulation
CN102014627B (zh) 2008-04-30 2014-10-29 国家卫生研究院 作为极光激酶抑制剂的稠合双环嘧啶化合物
US20110112193A1 (en) * 2008-05-14 2011-05-12 Peter Nilsson Bis-aryl compounds for use as medicaments
JP5684719B2 (ja) * 2008-12-05 2015-03-18 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｐｌｋ阻害剤としての５，７−ジヒドロ−６ｈ−ピリミド［５、−４ｄ］［１］ベンゾアゼピン−６−チオン
WO2010074724A1 (en) 2008-12-22 2010-07-01 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-cd20 antibodies
EP2406223A2 (en) 2009-03-12 2012-01-18 Biolipox AB Bis aromatic compounds for use as ltc4 synthase inhibitors
JP2012520275A (ja) 2009-03-12 2012-09-06 バイオリポックス エービー Ｌｔｃ４シンターゼ阻害剤としての使用のためのビス芳香族化合物
US20120004228A1 (en) 2009-03-12 2012-01-05 Biolipox Ab Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors
EP2429994A1 (en) 2009-03-12 2012-03-21 Biolipox AB Bis aromatic compounds for use as ltc4 synthase inhibitors
US8546377B2 (en) * 2009-04-23 2013-10-01 Abbvie Inc. Modulators of 5-HT receptors and methods of use thereof
US8518933B2 (en) 2009-04-23 2013-08-27 Abbvie Inc. Modulators of 5-HT receptors and methods of use thereof
JO3635B1 (ar) * 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
JO3434B1 (ar) 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
JP2013520424A (ja) * 2010-02-19 2013-06-06 ミレニアム ファーマシューティカルズ， インコーポレイテッド ナトリウム４−｛［９−クロロ−７−（２−フルオロ−６−メトキシフェニル）−５Ｈ−ピリミド［５，４−ｄ］［２］ベンゾアゼピン−２−イル］アミノ｝−２−メトキシベンゾエートの結晶形
EP2545036A1 (en) 2010-03-12 2013-01-16 Biolipox AB Bis aromatic compounds for use as ltc4 synthase inhibitors
TW201316991A (zh) 2011-06-03 2013-05-01 Millennium Pharm Inc Ｍｅｋ抑制劑與奧諾拉（ａｕｒｏｒａ）ａ激酶選擇性抑制劑之組合
GB201202027D0 (en) * 2012-02-06 2012-03-21 Sareum Ltd Pharmaceutical compounds
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
AU2013234955A1 (en) 2012-03-23 2014-11-13 Dennis Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
CN103804391A (zh) * 2012-11-01 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
US9724354B2 (en) 2013-03-22 2017-08-08 Millennium Pharmaceuticals, Inc. Combination of catalytic mTORC1/2 inhibitors and selective inhibitors of Aurora A kinase
CN103408552B (zh) * 2013-07-25 2015-07-01 苏州明锐医药科技有限公司 阿立塞替的制备方法
WO2015085289A1 (en) 2013-12-06 2015-06-11 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-cd30 antibodies
WO2017015316A1 (en) * 2015-07-21 2017-01-26 Millennium Pharmaceuticals, Inc. Administration of aurora kinase inhibitor and chemotherapeutic agents
WO2019195658A1 (en) 2018-04-05 2019-10-10 Dana-Farber Cancer Institute, Inc. Sting levels as a biomarker for cancer immunotherapy
SG11202106635WA (en) 2018-12-21 2021-07-29 Daiichi Sankyo Co Ltd Combination of antibody-drug conjugate and kinase inhibitor
US20220305048A1 (en) 2019-08-26 2022-09-29 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling
CN112062768B (zh) * 2020-07-20 2021-08-31 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 具有Aurora激酶降解活性的小分子及其制备方法和应用
TW202340206A (zh) * 2021-12-14 2023-10-16 南韓商普瑞澤治療公司 藉由多重泛素化使標的蛋白或多肽降解的化合物或其醫藥上可接受之鹽類、異構物、溶劑合物、水合物或前驅藥、及包含其之醫藥組成物

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3947585A (en) 1974-06-03 1976-03-30 Ciba-Geigy Corporation Pyrazolobenzazepines
US4022801A (en) 1974-06-03 1977-05-10 Ciba-Geigy Corporation Pyrazolobenzazepines
US4028381A (en) 1975-05-05 1977-06-07 Ciba-Geigy Corporation Pyrazolobenzazepines
US4099012A (en) 1975-08-28 1978-07-04 Ciba-Geigy Corporation 2-pyrazolyl-benzophenones
NL8000715A (nl) 1979-02-07 1980-08-11 Hoffmann La Roche Pyrimido-2-benzazepinen, werkwijzen ter bereiding ervan, alsmede farmaceutische preparaten, die deze pyrimido-2- benzazepinen bevatten.
US4547581A (en) 1979-02-07 1985-10-15 Hoffmann-La Roche Inc. Pyrimido-2-benzazepines and intermediates in their preparation
KR840000061B1 (ko) 1979-02-07 1984-01-31 에프. 호프만-라 롯슈 앤드 캄파니 아크티엔 게젤샤프트 벤즈아제핀 유도체의 제조방법
US4481142A (en) 1979-02-07 1984-11-06 Hoffmann-La Roche Inc. Pyrimido-2-benzazepines
US4318854A (en) 1979-02-07 1982-03-09 Hoffmann-La Roche Inc. Intermediates in the production of 2-benzazepines
ZA80492B (en) * 1979-02-07 1981-01-28 Hoffmann La Roche Benzazepine derivatives
US4469633A (en) 1980-05-16 1984-09-04 Hoffmann-La Roche Inc. N-oxides of 5-oxo-1-phenyl-2-benzazepines
NL8102182A (nl) 1981-05-04 1982-12-01 Philips Nv Kleurenbeeldbuis.
EP0273697A3 (en) 1986-12-30 1989-11-29 Merck & Co. Inc. 2-benzazepines with 5- and 6- membered heterocyclic rings
US5166151A (en) 1988-03-25 1992-11-24 Merck & Co., Inc. 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof
US5210082A (en) 1991-05-16 1993-05-11 Merck & Co., Inc. 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders
US5747487A (en) 1993-07-29 1998-05-05 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
IL126095A0 (en) 1996-03-08 1999-05-09 Zeneca Ltd Azolobenzazepine derivatives as neurogically active agents
JP2001507349A (ja) * 1996-12-23 2001-06-05 セルテック セラピューティックス リミテッド 縮合多環式２−アミノピリミジン誘導体、それらの製造およびたんぱく質チロシンキナーゼ抑制因子としてのそれらの使用
ES2191963T3 (es) 1997-09-29 2003-09-16 Meiji Seika Kaisha Derivados triciclicos de triazolobenzazepina, proceso para la obtencion de los mismos y agentes antialergicos.
US6277844B1 (en) 1998-09-14 2001-08-21 Sydney Spector Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis
AU4841700A (en) 1999-05-12 2000-11-21 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
HUP0302411A2 (hu) * 2000-09-15 2003-11-28 Vertex Pharmaceuticals Incorporated Proteinkináz inhibitorként alkalmazható pirazolvegyületek és ezeket tartalmazó gyógyszerkészítmények
WO2002068415A1 (en) 2000-12-21 2002-09-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6686352B2 (en) 2001-05-18 2004-02-03 Hoffmann-La Roche Inc. Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
NZ530741A (en) 2001-08-09 2006-08-31 Actelion Pharmaceuticals Ltd Novel benzo-fused heterocycles as endothelin antagonists
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
MY139355A (en) 2004-05-14 2009-09-30 Millennium Pharm Inc Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase
BRPI0517737A (pt) 2004-11-17 2008-10-21 Miikana Therapeutics Inc inibidores de quinase
WO2006070198A1 (en) 2004-12-30 2006-07-06 Astex Therapeutics Limited Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
US20090203671A1 (en) 2007-11-27 2009-08-13 Abbott Laboratories Method of treating cancer
JO3434B1 (ar) * 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8624027B2 (en) 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein

Also Published As

Publication number Publication date
CN104193750A (zh) 2014-12-10
KR20120091275A (ko) 2012-08-17
RS52436B (en) 2013-02-28
EP1771450B9 (en) 2008-12-24
US20220041605A1 (en) 2022-02-10
US7572784B2 (en) 2009-08-11
EP1771450A2 (en) 2007-04-11
MY139355A (en) 2009-09-30
DE602005003951T2 (de) 2008-12-11
RS50568B9 (sr) 2019-06-28
WO2005111039A2 (en) 2005-11-24
US9102678B2 (en) 2015-08-11
KR20070011606A (ko) 2007-01-24
HRP20080120T3 (en) 2008-04-30
US20160185782A1 (en) 2016-06-30
AU2005243175B2 (en) 2011-12-01
AU2005243175A1 (en) 2005-11-24
AR049277A1 (es) 2006-07-12
DK1771450T3 (da) 2008-04-28
KR101748290B1 (ko) 2017-06-16
DK1771450T5 (da) 2012-01-09
US20050256102A1 (en) 2005-11-17
WO2005111039A3 (en) 2006-04-20
US9765078B2 (en) 2017-09-19
US11014928B2 (en) 2021-05-25
NZ551370A (en) 2009-08-28
JP2014114319A (ja) 2014-06-26
ATE381566T1 (de) 2008-01-15
EP2746285B1 (en) 2016-09-14
EP2719698B1 (en) 2016-10-05
JP2008285484A (ja) 2008-11-27
PT1905773E (pt) 2012-10-25
HK1102500A1 (en) 2007-11-23
BRPI0511139B8 (pt) 2021-05-25
US10414770B2 (en) 2019-09-17
TW200604192A (en) 2006-02-01
DE602005003951T4 (de) 2012-10-11
MXPA06013042A (es) 2007-02-12
EP2746285A1 (en) 2014-06-25
PL1771450T3 (pl) 2008-05-30
BRPI0511139B1 (pt) 2019-05-21
KR101792651B1 (ko) 2017-11-20
TWI338688B (en) 2011-03-11
EP2261226B1 (en) 2015-04-01
US20200247810A1 (en) 2020-08-06
DE602005003951D1 (de) 2008-01-31
HK1199254A1 (en) 2015-06-26
US20090299060A1 (en) 2009-12-03
ES2391577T3 (es) 2012-11-27
US20140046055A1 (en) 2014-02-13
EP1771450B1 (en) 2007-12-19
IL179063A0 (en) 2007-03-08
IL179063A (en) 2016-05-31
US8399659B2 (en) 2013-03-19
ES2299080T3 (es) 2008-05-16
EP2261226A1 (en) 2010-12-15
JP4467616B2 (ja) 2010-05-26
HK1114853A1 (en) 2008-11-14
HK1205102A1 (en) 2015-12-11
KR20130073993A (ko) 2013-07-03
CN104193750B (zh) 2018-04-27
BRPI0511139A (pt) 2007-11-27
CA2565411A1 (en) 2005-11-24
JP2012006972A (ja) 2012-01-12
CA2565411C (en) 2010-04-20
EP2719698A1 (en) 2014-04-16
CY1113192T1 (el) 2016-04-13
ES2540987T3 (es) 2015-07-15
JP2007537268A (ja) 2007-12-20
US20180134716A1 (en) 2018-05-17
RS50568B (sr) 2010-05-07
HRP20120785T1 (hr) 2012-11-30
US20240083906A1 (en) 2024-03-14
HRP20080120T5 (hr) 2012-07-31
JP5148358B2 (ja) 2013-02-20
PT1771450E (pt) 2008-03-31
JP5827708B2 (ja) 2015-12-02
RS50568B8 (sr) 2019-08-30
CY1108092T1 (el) 2014-02-12
EA012112B1 (ru) 2009-08-28
US20070185087A1 (en) 2007-08-09

Similar Documents

Publication Publication Date Title
EA200602100A1 (ru) Соединения и способы для ингибирования митотической прогрессии
HUS2100051I1 (hu) Kompozíciók és eljárások sejtproliferációs rendellenességek kezelésére
TW200801008A (en) Protein kinase inhibitors
EA200970486A1 (ru) Соединения для ингибирования митоза
EA200870415A1 (ru) Хиназолины для ингибирования pdk 1
WO2008021038A3 (en) Pyridobenzazepine compounds and methods for inhibiting mitotic progression
MX2007011545A (es) Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr.
ATE421512T1 (de) Inhibitoren von mitotischem kinesin
ATE497496T1 (de) 2,4-pyridimediamon-derivate als hemmer von jak- kinasen zur behandlung von autoimmunerkrankungen
WO2007067781A3 (en) 9-membered heterobicyclic compounds as inhibitors of protein kinases
DE60222302D1 (de) Inhibitoren von mitotischem kinesin
ATE356804T1 (de) Inhibitoren von mitotischem kinesin
ATE424388T1 (de) Mitotische kinesinhemmer
ATE447577T1 (de) Mitotische kinesin-hemmer
EA200900571A1 (ru) Композиции chk1 ингибиторов
ATE554087T1 (de) Neue kinaseinhibitoren
ATE446094T1 (de) Mitotische kinesin-hemmer
DK1648905T3 (da) Inhibitorer for thienopyridin- og furopyridinkinase
DE60329990D1 (de) Mitotische kinesin-hemmer
NO20061194L (no) Mitotiske kinesininbibitorer
EA200800374A1 (ru) 1,4-дигидропиридин-конденсированные гетероциклы, способы их получения, применение и содержащие их композиции
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
MXPA05006507A (es) Inhibidores de ccxckr2 expresado en tumor humano.
MX2009012079A (es) Compuestos heterociclicos condensados como inhibidores de proteina cinasas.
ATE426605T1 (de) Inhibitoren von mitotischem kinesin

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG MD TJ TM